Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Amicus Therapeutics (FOLD) PT Lowered to $13 at BofA Securities
May 10, 2024 5:27 AM EDTBofA Securities analyst Tazeen Ahmad lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $13.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "FOLD reported 1Q Pombiliti+Opfolda (P&O) sales of $11mn and provided FY24 sales guidance of $62-67mn.... More
Amicus Therapeutics (FOLD) PT Lowered to $19 at Morgan Stanley
May 9, 2024 12:03 PM EDTMorgan Stanley analyst Jeffrey Hung lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $19.00 (from $20.00) while maintaining a Underweight rating.
The analyst comments "1Q earnings were in line with Street expectations for Galafold and below on Pombiliti + Opfolda (P+O). The company... More
